Veru Inc EV / EBITDA
Was ist das EV / EBITDA von Veru Inc?
EV / EBITDA von Veru Inc ist N/A
Was ist die Definition von EV / EBITDA?
EV / EBITDA ist der Unternehmenswert geteilt durch das Einkommen vor Zinsen, Steuern, Abschreibungen und Amortisationen. Es ist ein Maß dafür, wie teuer eine Aktie ist und für Vergleiche zwischen Unternehmen häufiger gültig ist als das Preis-Gewinn-Verhältnis. Er misst den Preis (in Form des Unternehmenswerts), den ein Investor zu Gunsten des Cashflows des Unternehmens (in Form des EBITDA) bezahlt.
Price to earnings ratios are impacted by a company's choice of capital structure - companies which raise money via debt will have lower P/Es (and therefore look cheaper) than companies that raise an equivalent amount of money by issuing shares, even though the two companies might have equivalent enterprise values. A sample case is when a company with debt were to raise money by issuing shares of stock, and then used the money to pay off the debt, this company's P/E ratio would shoot up because of the increased number of shares - although nothing about the fundamental value of the business has changed. EV / EBITDA is unaffected by capital structure as enterprise value includes the value of debt, and EBITDA is available to all investors (debt and equity) as it excludes interest payments on that debt. It is ideal for analysts and potential investors looking to compare companies within the same industry.
EV / EBITDA von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu Veru Inc
Was macht Veru Inc?
the female health company/veru healthcare is a therapeutics company focused on developing and commercializing pharmaceuticals and devices in men’s and women’s health and oncology. to realize this goal, veru healthcare has three divisions: pharmaceutical and devices, consumer health products, and public sector. for men, product and product candidates are in the areas of benign prostatic hyperplasia, male infertility, amelioration of side effects of hormonal prostate cancer therapies, prostate cancer, gout, and sexual dysfunction. women’s health has product candidates for female sexual health and advanced breast and ovarian cancers and markets fc2, a disposable contraceptive device, to ob gyn physicians and is the only female condom approved by fda that offers dual protection against sexually transmitted infections, including hiv/aids and the zika virus, and unintended pregnancy. since the female health company began distributing fc2 in 2007, the product has been shipped to 144 countries
Unternehmen mit ev / ebitda ähnlich Veru Inc
- Annovis Bio hat EV / EBITDA von N/A
- Newtopia hat EV / EBITDA von N/A
- Branded Legacy Inc hat EV / EBITDA von N/A
- 23228 hat EV / EBITDA von N/A
- Centurion Minerals hat EV / EBITDA von N/A
- URA Plc hat EV / EBITDA von N/A
- Veru Inc hat EV / EBITDA von N/A
- Dynamo Capital hat EV / EBITDA von N/A
- Esports Mogul hat EV / EBITDA von N/A
- FireFox Gold hat EV / EBITDA von N/A
- SecureWorks Corp hat EV / EBITDA von N/A
- Armada Metals Ltd hat EV / EBITDA von N/A
- BriaCell Therapeutics hat EV / EBITDA von N/A